Compare LIQT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIQT | LEXX |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Denmark | Canada |
| Employees | N/A | 7 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 16.2M |
| IPO Year | 2011 | N/A |
| Metric | LIQT | LEXX |
|---|---|---|
| Price | $1.40 | $0.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.30 | $1.50 |
| AVG Volume (30 Days) | 8.6K | ★ 132.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.32 | N/A |
| Revenue Next Year | $71.69 | $601.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.34 | $0.46 |
| 52 Week High | $3.35 | $1.90 |
| Indicator | LIQT | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 39.90 | 47.95 |
| Support Level | N/A | $0.58 |
| Resistance Level | $2.00 | $0.87 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 10.00 | 38.33 |
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in businesses that are liquid filtration market and the silicon carbide ceramic membrane & diesel particulate filter (DPF) market. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and others. Its operating segment includes Water, Ceramics, and Plastics.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.